Image
Image
Image 2
Image 2
Image 3
Image 3
Image 4
Image 4
Image 5
Image 5
Image 6
Image 6
Image 7
Image 7
Image 8
Image 8
Image 9
Image 9
Nasopharyngeal carcinoma is strongly associated with Epstein-Barr virus (EBV) in non-keratinizing and basaloid subtypes, particularly in Asian populations, whereas keratinizing type shares risk factors of smoking and alcohol common to other head and neck squamous cell carcinomas.
Clinical presentation is often delayed until advanced stage because early symptoms (nasal obstruction, epistaxis, conductive hearing loss from Eustachian tube obstruction) are overlooked, leading to high rates of nodal metastases and distant spread at diagnosis.
Retropharyngeal nodes are usually the first nodes involved, but in up to 35% of cases these nodes are skipped and level II nodes are involved first, requiring careful assessment of the entire cervical lymph node chain.
MRI is the modality of choice for staging due to superior soft tissue resolution and sensitivity for perineural spread and intracranial extension, whereas CT is ideal for early detection of bony skull base involvement.
Post-radiotherapy fibrosis can be distinguished from residual or recurrent tumor on MRI only when mature (low T2 signal, no enhancement), but early fibrotic change cannot be reliably distinguished and may require follow-up imaging or PET.
F-18 FDG-PET is highly sensitive for detecting nodal metastases and recurrent disease and is the modality of choice for surveillance after treatment.
Clearly identify the tumor's origin at the fossa of Rosenmüller and describe the pattern and extent of skull base involvement (specify which foramina or bone structures are affected), lymph node levels involved (particularly status of retropharyngeal and level II nodes), and presence or absence of perineural spread and intracranial extension, as these findings directly impact TNM staging and treatment planning.